Program

Czwartek, 22 kwietnia 2027

GDAŃSK, POLAND | 22–24 APRIL 2027

19:00	**Get-together (Faculty Only)**

Piątek, 23 kwietnia 2027

GDAŃSK, POLAND | 22–24 APRIL 2027

08:30–08:35	**Welcome** *prof. dr hab. n. med. Krzysztof Narkiewicz, prof. Michel Burnier*
08:35–09:50	**Session 1. From biomarkers to clinical decisions — what really changes practice** *Chairs: prof. dr hab. n. med. Andrzej Januszewicz, prof. Alexandre Persu*
08:35–08:50	Why do we need biomarkers — what do they add beyond conventional risk factors? *Carmine Zoccali*
08:50–09:05	Different biomarkers, different questions *Francesca Mallamaci*
09:05–09:20	From association to clinical utility — how should a new biomarker be validated? *prof. Christian Delles*

09:20–09:35	When should a biomarker change treatment?
09:35–09:50	Discussion
09:50–10:10	**Coffee break**
10:10–12:10	**Session 2. Hypertension in 2027: promises and disappointments in biomarkers, risk stratification and treatment targets**
10:10–10:25	Homocysteine and B vitamins — old story, new evidence?
10:25–10:40	Inflammation and vascular dysfunction in hypertension — does hsCRP add value? *Daniela Carnevale*
10:40–10:55	hs-Troponin and NT-proBNP — ready for risk stratification in hypertension? *prof. Gianfranco Parati*
10:55–11:10	MicroRNAs — still promising or a missed opportunity?
11:10–11:25	Renin and aldosterone — can we use them to guide treatment?
11:25–11:40	Sympathetic activation — can we identify and treat the phenotype? *Stefano Masi*
11:40–12:10	Discussion
12:30–14:00	**Lunch**
14:00–16:00	**Session 3. Biomarkers in CKD — from progression to nephroprotective treatment** *Chairs: Liffert Vogt, prof. Michel Burnier*
14:00–14:15	New blood and urine biomarkers — do they improve risk prediction?

14:15–14:30	Tubular biomarkers — can they improve assessment of kidney injury and progression? *. Marius Miglinas*
14:30–14:45	Albuminuria and eGFR slope — still the benchmarks? *Alberto Ortiz*
14:45–15:00	Afamin — promising biomarker or another association?
15:00–15:15	pre-CKD (hrCKD) — new clinical entity in nephrology defined by biomarkers *prof. dr hab. n. med. Marcin Adamczak*
15:15–15:30	From risk prediction to treatment selection — can biomarkers guide nephroprotection? *prof. dr hab. n. med. Andrzej Więcek*
15:30–16:00	Discussion
16:00–16:20	**Coffee break**
16:25–17:35	**Session 4. Heart Failure: from biomarkers to precision therapy and proactive care** *Chairs: prof. Gianfranco Parati, Piotr Ponikowski*
16:25–16:32	From molecular signatures to treatable endotypes: can multi-omics guide heart failure therapy?
16:32–16:44	Precision decongestion: urine sodium and beyond *dr hab. n. med., prof. UMW Jan Biegus*
16:44–16:56	From blood tests to biosensors: towards real-time monitoring in heart failure
16:56–17:08	From multi-modal monitoring to supported self-management: can we prevent worsening heart failure?
17:08–17:20	Biomarker-guided precision medicine in heart failure: promise or clinical reality? *prof. dr hab. n. med. Ewa Jankowska*

17:20–17:35	Panel discussion: from biomarker signals to clinical decisions — what is ready for practice?

Sobota, 24 kwietnia 2027

GDAŃSK, POLAND | 22–24 APRIL 2027

09:00–10:15	**Session 5. Beyond blood biomarkers — digital phenotyping and imaging**
09:00–09:15	Digital biomarkers in peripheral artery disease — ready for clinical use?
09:15–09:30	Renal MRI biomarkers — from tissue characterization to clinical decisions
09:30–09:45	Imaging biomarkers for Kidney Function and Disease: MRI and beyond *dr Anna Caroli*
09:45–10:00	Cardiac CT and MRI biomarkers — what changes clinical management?
10:00–10:15	Discussion
10:15–10:35	**Coffee break**
10:35–11:50	**Session 6. The future of biomarkers — what comes next?** *Chairs: dr Jan Danser, prof. dr hab. n. med. Krzysztof Narkiewicz*
10:35–10:50	From biomarkers to physiology — what can we learn from the kidney?
10:50–11:05	Will genetic biomarkers change clinical practice? *Olle Melander*

11:05–11:20	Risk assessment in hypertension — where will biomarkers fit?
11:20–11:35	From cardiovascular risk prediction to treatment — which biomarkers will really matter in 2030?
11:35–11:50	Discussion
11:50–12:30	**Discussion and closure of the meeting** *Chairs: prof. dr hab. n. med. Krzysztof Narkiewicz, prof. Michel Burnier*
13:00	**Lunch**